WeVote
Log In

Bill

Bill

HB 483

Prescription Drug Affordability Board; established.

2026 Regular Session Introduced by Nadarius Clark and 7 co-sponsors

Virginia establishes a Prescription Drug Affordability Board to review and report on high drug costs and recommend affordability solutions to lawmakers.

Governor's recommendation received by House
0
WeVote Research Nonpartisan
Bill Summary · HB 483

Legislative bill overview

HB 483 establishes a Prescription Drug Affordability Board in Virginia tasked with reviewing drug costs and identifying prescription medications with significant affordability challenges. The board would analyze pricing data and submit reports to the General Assembly on findings and recommendations for addressing high drug costs.

Why is this important

Prescription drug costs significantly impact healthcare affordability for Virginia residents and state budgets. The board would provide data-driven analysis to inform future policy decisions about drug pricing, potentially affecting patients' access to medications and state healthcare spending.

Potential points of contention

  • Cost and implementation: The fiscal impact statement suggests state funding requirements; opponents may question whether the board's benefits justify its operational costs versus other healthcare spending priorities
  • Scope of authority: Disagreement exists over whether the board should have investigative/regulatory powers or remain advisory-only, and how it interacts with federal drug pricing oversight
  • Pharmaceutical industry concerns: Industry stakeholders may argue the board duplicates existing FDA oversight or could discourage drug development and investment in Virginia

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.